Outlook Therapeutics (FRA:41O) Net Income (Continuing Operations) : €-146.65 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Outlook Therapeutics's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was €-105.15 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was €-146.65 Mil.

Outlook Therapeutics Net Income (Continuing Operations) Historical Data

The historical data trend for Outlook Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Net Income (Continuing Operations) Chart

Outlook Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-31.35

-29.92

-45.19

-66.71

-55.27

Outlook Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															-6.22	-19.08	-12.17	-10.25	-105.15

Outlook Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-146.65 Mil.

Outlook Therapeutics (FRA:41O) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Outlook Therapeutics Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (FRA:41O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

OTLK:USA 41ON:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines